Pharmaceuticals, Biotechnology and Life Sciences
Novocure’s Optune has became the first innovative treatment for glioblastoma approved in China in over 15 years, the company said in a Wednesday press release, after it’s global phase 3 pivotal clinical study in newly diagnosed glioblastoma showed adding Optune to chemotherapy more than doubled the five-year overall survival rate.
Novocure has posted quarterly net revenues of $101.8 million, representing 39 percent growth versus the first quarter 2019 and 3 percent growth versus the fourth quarter 2019.
Novocure will present EF-19 data which confirm the effectiveness and safety of Optune as monotherapy and further strengthen Optune’s clinical profile in recurrent GBM.
Novocure (NASDAQ: NVCR) today announced the U.S Centers for Medicare & Medicaid Services (CMS) has established a 2019 monthly fee schedule amount for Optune.
Novocure announced today that it will report financial results for the second quarter 2019 on Thursday, July 25, 2019, before the U.S. financial markets open.
The study provides a definition for Tumor Treating Fields dose and sets a framework for future work on Tumor Treating…
The publication of the 2018 Annual Report marks the public debut ofNovocure’s newly defined vision, mission and values. Novocure launchedits vision, mission and values internally to its nearly 600 employees atthe end of 2018.
INNOVATE-3 will test the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer ST.…
A special symposium session, intended to highlight therapeutic advances, will focus on Tumor Treating Fields as a fourth modality in…
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the retirement of Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head…